Pharmacokinetics of single-agent axitinib across multiple solid tumor types
- 22 October 2014
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 74 (6) , 1279-1289
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic MelanomaClinical Cancer Research, 2011
- Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptorTargeted Oncology, 2009
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II StudyJournal of Clinical Oncology, 2009
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3Clinical Cancer Research, 2008
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II StudyJournal of Clinical Oncology, 2008
- Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II studyThe Lancet Oncology, 2007
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005
- Effective Half‐Life in Clinical PharmacologyThe Journal of Clinical Pharmacology, 1995